NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Forecast & News

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its earnings results on Friday, February, 14th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. View Fennec Pharmaceuticals' Earnings History.

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Fennec Pharmaceuticals.

2 brokers have issued twelve-month target prices for Fennec Pharmaceuticals' shares. Their forecasts range from $16.00 to $17.00. On average, they expect Fennec Pharmaceuticals' share price to reach $16.50 in the next twelve months. This suggests a possible upside of 104.7% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.

Headlines about FENC stock have trended somewhat positive on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Fennec Pharmaceuticals.

Fennec Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 499,300 shares, an increase of 6.4% from the January 15th total of 469,400 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is currently 13.4 days. Approximately 3.0% of the shares of the company are sold short. View Fennec Pharmaceuticals' Current Options Chain.

Some companies that are related to Fennec Pharmaceuticals include MeiraGTx (MGTX), Aptose Biosciences (APTO), Replimune Group (REPL), Prevail Therapeutics (PRVL), Nantkwest (NK), Agenus (AGEN), Compugen (CGEN), Voyager Therapeutics (VYGR), Translate Bio (TBIO), Autolus Therapeutics (AUTL), Cabaletta Bio (CABA), BioCryst Pharmaceuticals (BCRX), Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI) and Precision BioSciences (DTIL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Amarin (AMRN), Fate Therapeutics (FATE), Allena Pharmaceuticals (ALNA), Coherus Biosciences (CHRS), Denali Therapeutics (DNLI), Karyopharm Therapeutics (KPTI), Pieris Pharmaceuticals (PIRS), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

Fennec Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Kam Lawrence (4.20%), Oxford Asset Management LLP (0.30%), Hartford Financial Management Inc. (0.18%), Wedbush Securities Inc. (0.12%), Renaissance Technologies LLC (0.12%) and Goldman Sachs Group Inc. (0.07%). View Institutional Ownership Trends for Fennec Pharmaceuticals.

FENC stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Victory Capital Management Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

FENC stock was acquired by a variety of institutional investors in the last quarter, including Kam Lawrence, Renaissance Technologies LLC, Goldman Sachs Group Inc., Wedbush Securities Inc. and Hartford Financial Management Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FENC stock can currently be purchased for approximately $8.06.

Fennec Pharmaceuticals has a market capitalization of $160.36 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. View Additional Information About Fennec Pharmaceuticals.

The official website for Fennec Pharmaceuticals is http://www.fennecpharma.com/.

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.